News

Women who reach menopause prematurely — meaning before age 40 — are two times more likely to develop pulmonary hypertension (PH) than those who do not, a study found. Analysis of medical records covering over 150,000 women registered in the U.K. Biobank also showed that this risk was not associated…

Although pregnancy should be avoided by women with severe pulmonary hypertension (PH), close monitoring by a multidisciplinary team may make it possible in those with moderate PH, a study from China suggests. The study “Long-term outcomes of pregnant women with pulmonary hypertension diagnosed by echocardiography: a…

Pulmonary hypertension (PH) occurs in 60% of children with the heart defect known as patent ductus arteriosus, with girls being more likely to develop PH than boys, a study found. A child with patent ductus arteriosus has an opening, or duct, between two major blood vessels leading from the…

Intravenous use of Uptravi (selexipag) is safe and well-tolerated by pulmonary arterial hypertension (PAH) patients temporarily unable to take this therapy as an oral tablet, a trial found. Patients reported mild side effects from the switch, with the most frequent being common to both oral and intravenous delivery of Uptravi. The…

A six-month exercise training program can significantly improve physical and psychological well-being in patients with pulmonary hypertension (PH), according to results of a new trial. The study, “Long-Term Effect of an Exercise Training Program on Physical Functioning and Quality of Life in Pulmonary Hypertension: A Randomized Controlled Trial,”…

Despite having lower respiratory muscle strength, people with pulmonary arterial hypertension (PAH) can still use dry powder inhalers that require breath-actuated force to effectively deliver inhaled therapies, a study has found. The study, “Impact of human behavior on inspiratory flow profiles in patients with pulmonary arterial…

The Pulmonary Hypertension Association (PHA) has published a guide that aims to help people recently diagnosed with pulmonary hypertension (PH), as well as their family and caregivers, in better managing the chronic lung disease. The 60-page book, titled “Navigating Pulmonary Hypertension: A Guide for Newly Diagnosed Patients,” covers…

VivaLNK’s wireless device can now be used to capture changes in heart rate and electrical activity in people with pulmonary hypertension (PH) or other disorders during the six-minute walk test (6MWT), a routine exercise endurance test. This wearable electrocardiography (ECG) monitor allows for in-clinic and remote patient…

Top-line data from a Phase 1 clinical trial has found that treprostinil palmitil inhalation powder (TPIP) — a dry powder form of a treprostinil precursor that is being developed by Insmed for treating pulmonary arterial hypertension (PAH) — was safe and well-tolerated in healthy volunteers. Results also showed…

Rare Disease Day at NIH, organized by the National Institutes of Health (NIH) and taking place on March 1, will feature panel discussions, patient stories, research updates, TED-style talks, and a presentation by a Nobel laureate recently recognized for her work on a gene editing tool. The free, virtual…